Klein R, Krüger G R, Sesterhenn K
Z Hautkr. 1978 Feb 1;53(3):62-6.
In the present study, we determined the absolute and the percental numbers of T-lymphocytes in 113 patients with malignant melanomas, of whom 50 had metastases and 63 did not. The findings were compared to those in a control group of 22 persons. The patients with melanomas were divided up into clinical stages: stage I (primary tumour), II (metastases in the local lymph nodes), and stage III (systemic metastases). There was a statistically significant reduction of T-lymphocytes in all patients with melanomas, but there were no significant differences between the three stages. Therapy with DTIC did not lead to any major reduction in T-lymphocytes, possibly because of subsequent treatment with BCG. We found no clear correlation between the reduction of T-lymphocytes and an unfavourable prognosis.
在本研究中,我们测定了113例恶性黑色素瘤患者的T淋巴细胞绝对数量和百分比数量,其中50例有转移,63例无转移。将结果与22名对照组人员的结果进行比较。黑色素瘤患者被分为临床分期:I期(原发性肿瘤)、II期(局部淋巴结转移)和III期(全身转移)。所有黑色素瘤患者的T淋巴细胞均有统计学意义的减少,但三个阶段之间无显著差异。达卡巴嗪治疗并未导致T淋巴细胞的任何显著减少,可能是因为随后进行了卡介苗治疗。我们未发现T淋巴细胞减少与不良预后之间有明确关联。